ONCONASE® Malignant Mesothelioma Trial

Alfacell Corporation is currently conducting a centrally randomized, international, confirmatory Phase IIIb clinical trial of its lead investigational drug, ONCONASE® (ranpirnase) for patients with Malignant Mesothelioma.

Trial Abstract

Purpose
Randomized Phase III trial to compare the effectiveness of Ranpirnase + Doxorubicin vs. Doxorubicin in treating patients with Malignant Mesothelioma.

Eligibility
  • At least 21 years old
  • Measurable or evaluable disease
  • No CNS metastases
  • No more than one previous chemotherapy regimen
  • At least 6 weeks since chemotherapy
  • No previous doxorubicin

Treatment
Patients will be randomly assigned to one of two groups. Patients in one group will receive infusions of Ranpirnase weekly and Doxorubicin every 3 weeks for up to 18 weeks. Patients in group two will receive an infusion of doxorubicin alone every 3 weeks for up to 18 weeks. Patient symptoms will be assessed.

This abstract is intended to give a brief overview of this clinical trial. To help determine whether the trial is appropriate for an individual, selected major eligibility criteria are listed above. To obtain more details related to trial and the treatment plan, please contact Alfacell via e-mail at PatientInfo@alfacell.com, telephone at 732-652-4525, or fax at 732-652-4576.


Over 40 cancer treatment centers in the following countries are currently accepting patients:
  • United States
  • Canada
  • Germany
  • Italy
  • Poland
  • Australia
  • New Zealand


For more information on the study - including eligibility criteria and a list of investigator sites - please visit the following sites:

1998-2008, Alfacell Corporation
300 Atrium Drive, Somerset, NJ 08873
Phone: 732-652-4525   Fax: 732-652-4575
Please read our Disclaimer

  Home    Contact us